In a full-size leap forward inside the combat in opposition to HIV, america meals and Drug administration (FDA) has permitted lenacapavir, an extended-performing injectable remedy developed via Gilead Sciences, for the prevention of HIV infection.

The treatment is designed to be administered only twice a year, presenting an effective new alternative for adults and teenagers who’re at excessive threat of contracting the virus. This marks a chief milestone in efforts to reduce the worldwide burden of HIV, which continues to affect thousands and thousands round the world.

In contrast to conventional daily oral medicinal drugs for HIV prevention, lenacapavir gives a greater handy and discreet opportunity that would enhance adherence and accessibility, in particular in populations that conflict with taking day by day tablets. This new injectable treatment is predicted to provide a giant improvement to pre-publicity prophylaxis (PrEP) strategies, supporting to shut the space between human beings at danger and the preventive care they want.

The approval comes at a time whilst the global fight towards HIV remains far from over. In line with UNAIDS, nearly forty million humans were residing with HIV in 2023, and approximately 5.4 million of them had been unaware of their reputation.

The arena fitness company suggested that in the identical year, an anticipated 1.3 million human beings were newly infected with HIV, and 630,000 humans died from HIV-related causes. Those figures underscore the pressing want for modern and reachable prevention equipment like lenacapavir.

Public health specialists trust that the introduction of long-acting preventive options should transform the global response to HIV, especially in groups with restrained access to healthcare. The approval of lenacapavir brings new desire to millions and provides a vital device inside the ongoing assignment to quit the HIV epidemic.

Sources https://www.theweek.in/news/health/2025/06/22/hiv-prevention-drug-lenacapavir-gets-fda-nod-nearly-100-per-cent-effective-says-experts.html

https://news.google.com/read/CBMi1AFBVV95cUxOTDVnbjczR05YWDREU1M1UUlOTDc2OGxaT3ZmUUU1bDNfVXRGMllxQmJ6Y1VlM0pQUGlxYnFvQ2MycG5oWFBPOEJlV1ZvcUozTDk5MG5MWm1Dcy1QMFJ2Mml4TndXYV9PVUNjNS1pbFFPdjVfRFhzbnRWNjJ0NU9nVjNLbXRZeUtMcUZLbDhCUFZ1Q1J5NzlkcXV6QkNsaldHQkhxeFZJUzloMFhMbkp6NkRBei1fRk90Z3BGNnU4Z0ZzeWoydEdKRzdjbzlGdF9STWJkUNIB2gFBVV95cUxPSXp0RVVVQlBlVTllS3R3VFNld2JyQmN6MzFmd1ZWU2dtUDVsYXBtcktoWTlHVWVlaTBUWGM2VTFRaDlZemIza2ZvZWR4aThXV0NjakV2WE5temJlM0ZYcUxBaVlON1c3MWdCZUUtY28xblB0MzhnSmZWdE53MDJ2ZUVpYUY1V0RaOHd4ZFJYaTBGX1NWMmtCLWY0YkszZnV4dm1RSVM0MEl1clltTzJ1Z0NpLXEyVUdqdUkwQTMycFZtQlVocU05dnF2VTRsNVQ2ZTdaeDRMTjVDZw?hl=en-IN&gl=IN&ceid=IN%3Aen